dsp 4 has been researched along with Idiopathic Parkinson Disease in 13 studies
DSP 4: RN given refers to parent cpd
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paradoxically, these prodromal symptoms are indicative of a noradrenergic hyperactivity phenotype, rather than the predicted loss of norepinephrine (NE) transmission following LC damage, suggesting the engagement of complex compensatory mechanisms." | 1.91 | The Neurotoxin DSP-4 Dysregulates the Locus Coeruleus-Norepinephrine System and Recapitulates Molecular and Behavioral Aspects of Prodromal Neurodegenerative Disease. ( Dougherty, JD; Iannitelli, AF; Kelberman, MA; Korukonda, A; Liles, LC; Lustberg, DJ; McCann, KE; Mulvey, B; Segal, A; Sloan, SA; Weinshenker, D, 2023) |
| "Tremor was assessed visually and with accelerometers." | 1.91 | Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model. ( Asan, E; Biella, GEM; Bolzoni, F; Cavallari, P; Ip, CW; Isaias, IU; Pezzoli, G; Pozzi, NG; Volkmann, J, 2023) |
| "BACKGROUND AND PURPOSE Parkinson's disease (PD) is characterized by progressive dopaminergic cell loss; however, the noradrenergic system exhibits degeneration as well." | 1.38 | Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit. ( Giordano, G; Harkavyi, A; Lever, R; Rampersaud, N; Whitton, J; Whitton, P, 2012) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Iannitelli, AF | 1 |
| Kelberman, MA | 1 |
| Lustberg, DJ | 1 |
| Korukonda, A | 1 |
| McCann, KE | 1 |
| Mulvey, B | 1 |
| Segal, A | 1 |
| Liles, LC | 1 |
| Sloan, SA | 1 |
| Dougherty, JD | 1 |
| Weinshenker, D | 1 |
| Torrente, D | 1 |
| Su, EJ | 1 |
| Schielke, GP | 1 |
| Warnock, M | 1 |
| Mann, K | 1 |
| Lawrence, DA | 1 |
| Pozzi, NG | 1 |
| Bolzoni, F | 1 |
| Biella, GEM | 1 |
| Pezzoli, G | 1 |
| Ip, CW | 1 |
| Volkmann, J | 1 |
| Cavallari, P | 1 |
| Asan, E | 1 |
| Isaias, IU | 1 |
| Song, S | 1 |
| Wang, Q | 1 |
| Jiang, L | 1 |
| Oyarzabal, E | 1 |
| Riddick, NV | 1 |
| Wilson, B | 1 |
| Moy, SS | 1 |
| Shih, YI | 1 |
| Hong, JS | 1 |
| Shin, E | 1 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Björklund, A | 1 |
| Carta, M | 1 |
| Wang, Y | 1 |
| Wang, HS | 1 |
| Wang, T | 1 |
| Huang, C | 1 |
| Liu, J | 1 |
| Yao, N | 1 |
| Wu, Y | 1 |
| Zhou, Y | 1 |
| Ju, L | 1 |
| Liu, Y | 1 |
| Ju, R | 1 |
| Duan, D | 1 |
| Xu, Q | 1 |
| Ledreux, A | 1 |
| Boger, HA | 1 |
| Hinson, VK | 1 |
| Cantwell, K | 1 |
| Granholm, AC | 1 |
| Cao, LF | 1 |
| Peng, XY | 1 |
| Huang, Y | 1 |
| Wang, B | 1 |
| Zhou, FM | 1 |
| Cheng, RX | 1 |
| Chen, LH | 1 |
| Luo, WF | 1 |
| Liu, T | 1 |
| Rampersaud, N | 1 |
| Harkavyi, A | 1 |
| Giordano, G | 1 |
| Lever, R | 1 |
| Whitton, J | 1 |
| Whitton, P | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Jonsson, G | 1 |
| Magyar, K | 1 |
| Szende, B | 1 |
| Lengyel, J | 1 |
| Tarczali, J | 1 |
| Szatmáry, I | 1 |
2 reviews available for dsp 4 and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Chemical neurotoxins as denervation tools in neurobiology.
Topics: 5,6-Dihydroxytryptamine; 5,7-Dihydroxytryptamine; Animals; Benzylamines; Brain; Catecholamines; Dene | 1980 |
The neuroprotective and neuronal rescue effects of (-)-deprenyl.
Topics: Animals; Antiparkinson Agents; Benzylamines; Biotransformation; Brain; Humans; Melanoma; Neurons; Ne | 1998 |
11 other studies available for dsp 4 and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The Neurotoxin DSP-4 Dysregulates the Locus Coeruleus-Norepinephrine System and Recapitulates Molecular and Behavioral Aspects of Prodromal Neurodegenerative Disease.
Topics: Animals; Female; Locus Coeruleus; Male; Mice; Neurodegenerative Diseases; Neurotoxins; Norepinephrin | 2023 |
Opposing effects of β-2 and β-1 adrenergic receptor signaling on neuroinflammation and dopaminergic neuron survival in α-synuclein-mediated neurotoxicity.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Mice; Nerve Degeneration; Neuroinflammatory | 2023 |
Brain Noradrenergic Innervation Supports the Development of Parkinson's Tremor: A Study in a Reserpinized Rat Model.
Topics: Animals; Brain; Humans; Male; Norepinephrine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpi | 2023 |
Noradrenergic dysfunction accelerates LPS-elicited inflammation-related ascending sequential neurodegeneration and deficits in non-motor/motor functions.
Topics: Adrenergic Neurons; Aging; Animals; Benzylamines; Brain; Disease Models, Animal; Dopaminergic Neuron | 2019 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid | 2014 |
Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinson׳s disease.
Topics: Adrenergic Agents; Animals; Benzylamines; Calcium-Binding Proteins; Cells, Cultured; Coculture Techn | 2015 |
BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
Topics: Animals; Behavior, Animal; Benzylamines; Brain; Brain-Derived Neurotrophic Factor; Chaperonin 60; Co | 2016 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxid | 2016 |
Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.
Topics: Animals; Behavior, Animal; Benzylamines; Cerebrum; Disease Models, Animal; Dopamine; Exenatide; Male | 2012 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |